News for Immatics N.V. (IMTX)

We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Immatics N.V.

Immatics (IMTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Immatics N.V. targets cancer with its promising IMA203 pipeline. Learn why IMTX stock may be worth waiting for, despite solid data and a strong financial position.

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immatics (IMTX) delivered earnings and revenue surprises of 55.56% and 216.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[468977]**

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Tod

**media[460694]**

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aileron Therapeutics, Inc. (ALRN) experienced a notable stock movement with a 6.19% decline in its share price. The shares are now trading at $3.87 with a tradi

Japan-based BloomZ Inc. (BLMZ) is up over 95 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund holdings.

Baker Brothers' 13F portfolio value declines but continues to hold significant stakes in biopharmaceutical companies and boasts past successful. Read more here.

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month periods ended September 30, 2022, included herein, have... | November 17, 2022

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.